Alcidion Group (ASX: ALC) has signed an Asset Sale Agreement to acquire Telstra Health's Kyra Patient Flow Manager, Kyra Queue Manager, and Kyra IQ products.
This acquisition includes approximately 33 long-standing customers, with the top 10 customers averaging a ~10-year relationship tenure, and is anticipated to be earnings accretive from completion, which is expected by the end of June 2026.
Alcidion is funding the upfront cash purchase price of $3.0M from its existing cash reserves, having held $15.1M in cash with no debt as of 31 March 2026.
The Kyra suite is forecast to deliver $3.7M in revenue for FY26, with over 90% of this being recurring product revenue.
The acquisition implies an upfront underlying FY26 EBITDA multiple of 2.7x, based on a forecast underlying EBITDA of approximately $1.1M for FY26 from the acquired assets.
Strategic Fit and Market Position
This acquisition significantly strengthens Alcidion's enterprise patient flow capabilities, addressing both inpatient and outpatient patient flow and data access challenges.
It notably expands Alcidion's customer footprint across Australia, including a notable presence in Queensland, and additional customers in Victoria, Western Australia, and Tasmania across both public and private health sectors.
With only two of the 33 Kyra customers being existing Alcidion clients, the deal offers substantial opportunities for cross-selling and further expansion.
In addition to the $3.0M upfront cash payment, there is a potential earn-out of up to $1.0M, tied to achieving future recurring revenue thresholds over 12 months post-completion.
Context: Recent H1 FY26 Performance
This strategic move follows a period of strong performance for Alcidion.
In H1 FY26, the company reported revenue growth of 44% to $25.5M, with underlying EBITDA increasing 675% to $4.2M.
As at 31 December 2025, Alcidion had a contracted FY26 revenue base of $43.1M.
The company has reconfirmed its FY26 guidance, expecting revenue to exceed $50.0M and EBITDA to be greater than $5.0M, alongside positive operating cashflow.
AI Capability Clears Regulatory Hurdles
In a related development, Alcidion’s Miya Precision Concept Detection AI capability recently achieved dual Class I Software as a Medical Device (SaMD) registration in both Australia and the United Kingdom.
This registration enables the compliant commercial deployment of AI-assisted clinical documentation and decision-support tools across Alcidion's two largest markets.
This positions the company to leverage AI effectively within regulated procurement environments and to drive upsell opportunities for its existing customer base.
Alcidion's Strategic Acquisition
Alcidion's acquisition of Telstra Health's Kyra suite is a bold move to bolster its recurring revenue streams and expand its patient flow market share.
While execution risks remain, the deal's accretive nature and strategic fit with Alcidion's existing platform present a compelling growth opportunity.
